UBI Pharma Inc. - UBIP

News

Press Release

Our company's new compound drug NDF01 for the treatment of HIV infection has been approved by the Ministry of Health and Welfare
Learn More
Press Release

UBI Pharma announces its participation in the '2024 TALENT, in Taiwan' alliance for sustainable talent development in Taiwan."
Learn More
Press Release

UBI Pharma passes GMP inspection by the UK MHRA.
Learn More
Press Release

UBI Pharma applies to the Taiwan Food and Drug Administration (TFDA) for drug inspection registration of the biosimilar drug erythropoietin UB-851.
Learn More
Press Release

UBI Pharma passes GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
Learn More
Press Release

UBI Pharma obtains a US patent certificate for the "Single-Chain Immunoglobulin Fusion Protein Technology Platform."
Learn More
Press Release

UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).
Learn More
Press Release

UBI Pharma's proprietary product, Voriconazole Injection, has received approval for Abbreviated New Drug Application (ANDA) from the United States.
Learn More
Press Release

UBI Pharma Inc. responds to community greening and carbon reduction tree planting activities
Learn More
Press Release

UBI Pharma Inc. Achieves Another Milestone in the US Market: Its Anti-Fungal Injection Generic Product Approved by the US FDA
Learn More
Media Coverage

The UK's MHRA has cleared UBI's COVID-19 vaccine, UB-612, after inspecting its manufacturing facility. UBIP's production base in Taiwan has obtained GMP certification!
Learn More
Media Coverage

UBIP has completed the submission for its in-house developed biosimilar drug (UB-851, EPO) to TFDA
Learn More
Media Coverage

UBI Pharma Inc.'s "Single-Chain Immunoglobulin Fusion Protein Technology" has been granted a patent in the USA
Learn More
Media Coverage

Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc. to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market
Learn More
Media Coverage

UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023)
Learn More

About Us

The MOST TRUSTED Partner

Offers ONE-Stop Services

UBI Pharma Inc. stands as a distinguished pharmaceutical front-runner, focusing on the mastery of long-acting protein drugs and specialty injectables.

Establish Year

2014
CMO Products

100+
CDMO Projects

50+
International Inspection

11+
Footprint(sq. ft.)

240,000

What We Provide

01

Technology Platform

Global Vision

Leading Pharmaceutical Advancements

02

World Class Quality

Never Compromising on Quality • Trusted Worldwide

03

CMO & CDMO Services

One-stop service platform from development to manufacturing.

Best partner to bring concepts to fruition with a competitive price. Items include sterile injectables, capsules, tablets, ointments, and creams, etc.

Products

ESG

Investors